Cargando…

SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations

The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countri...

Descripción completa

Detalles Bibliográficos
Autores principales: Grabowski, Frederic, Preibisch, Grzegorz, Giziński, Stanisław, Kochańczyk, Marek, Lipniacki, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000749/
https://www.ncbi.nlm.nih.gov/pubmed/33804556
http://dx.doi.org/10.3390/v13030392
_version_ 1783671069216866304
author Grabowski, Frederic
Preibisch, Grzegorz
Giziński, Stanisław
Kochańczyk, Marek
Lipniacki, Tomasz
author_facet Grabowski, Frederic
Preibisch, Grzegorz
Giziński, Stanisław
Kochańczyk, Marek
Lipniacki, Tomasz
author_sort Grabowski, Frederic
collection PubMed
description The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countries that reported at least 50 genomes in January 2021. We have estimated that the replicative advantage of the VOC is in the range 1.83–2.18 [95% CI: 1.71–2.40] with respect to the 20A.EU1 variant that dominated in England in November 2020, and in range 1.65–1.72 [95% CI: 1.46–2.04] in Wales, Scotland, Denmark, and USA. As the VOC strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. We have estimated growth rates of expanding mutations acquired by the VOC lineage to find that the L18F substitution in spike has initiated a fast growing VOC substrain. The L18F substitution is of significance because it has been found to compromise binding of neutralizing antibodies. Of concern are immune escape mutations acquired by the VOC: E484K, F490S, S494P (in the receptor binding motif of spike) and Q677H, Q675H (in the proximity of the polybasic cleavage site at the S1/S2 boundary). These mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence.
format Online
Article
Text
id pubmed-8000749
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80007492021-03-28 SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations Grabowski, Frederic Preibisch, Grzegorz Giziński, Stanisław Kochańczyk, Marek Lipniacki, Tomasz Viruses Article The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countries that reported at least 50 genomes in January 2021. We have estimated that the replicative advantage of the VOC is in the range 1.83–2.18 [95% CI: 1.71–2.40] with respect to the 20A.EU1 variant that dominated in England in November 2020, and in range 1.65–1.72 [95% CI: 1.46–2.04] in Wales, Scotland, Denmark, and USA. As the VOC strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. We have estimated growth rates of expanding mutations acquired by the VOC lineage to find that the L18F substitution in spike has initiated a fast growing VOC substrain. The L18F substitution is of significance because it has been found to compromise binding of neutralizing antibodies. Of concern are immune escape mutations acquired by the VOC: E484K, F490S, S494P (in the receptor binding motif of spike) and Q677H, Q675H (in the proximity of the polybasic cleavage site at the S1/S2 boundary). These mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence. MDPI 2021-03-01 /pmc/articles/PMC8000749/ /pubmed/33804556 http://dx.doi.org/10.3390/v13030392 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Grabowski, Frederic
Preibisch, Grzegorz
Giziński, Stanisław
Kochańczyk, Marek
Lipniacki, Tomasz
SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
title SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
title_full SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
title_fullStr SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
title_full_unstemmed SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
title_short SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
title_sort sars-cov-2 variant of concern 202012/01 has about twofold replicative advantage and acquires concerning mutations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000749/
https://www.ncbi.nlm.nih.gov/pubmed/33804556
http://dx.doi.org/10.3390/v13030392
work_keys_str_mv AT grabowskifrederic sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations
AT preibischgrzegorz sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations
AT gizinskistanisław sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations
AT kochanczykmarek sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations
AT lipniackitomasz sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations